Comera SPAC Presentation Deck

Proprietary Pipeline Strategy Optimal Product Profile Comera Advantage Development Goal SQ formulations of widely used IV biologics Opportunity size validated by existing market Reduced efficacy and safety development risk with known molecular entity ● ● Products with high patient quality of life impact Chronically-administered therapies Patients affected by disruption to work and school due to IV infusion visits ● ● Select assets where SQore value can be leveraged High concentration protein solutions requiring viscosity reduction Stability challenges with viscosity reduction, addressable with SQore Achieve risk reduction and value creation in early milestones Consider asset out-licensing at key value inflection milestones (IND, Phase 1) Preserve option to continue full development to launch ● Comera LIFE SCIENCES 22

View entire presentation